United States Patent 6,866,839 (R,R)-Formoterol for COPD: Claim Scope, Patent Landscape, and Expiration/Challenge Pathways

Executive summary: US Patent 6,866,839 claims methods for treating chronic obstructive pulmonary disease (COPD) using enantiomerically enriched (R,R)-formoterol with ≥90% (R,R) and <10% (S,S), including dosage ranges and routes (notably inhalation and oral) and a specific salt embodiment (the fumarate dehydrate salt). The practical scope is concentrated on (i) enantiomer purity, (ii) COPD treatment, (iii) selected dosing windows designed to avoid racemic-associated adverse effects, and (iv) specific administration modalities. The competitive freedom-to-operate typically hinges on whether a competitor’s product uses an (R,R)-formoterol drug substance and whether its regulatory-grade enantiomeric purity falls within or outside the claimed purity band, plus whether dosage and “insufficient to cause racemic adverse effects” are structurally satisfied.

What is the scope of US Patent 6,866,839 and what do its claims cover?

Short answer: The patent covers method-of-treatment claims for COPD using (R,R)-formoterol that is enriched to at least 90% by weight (R,R) and contains less than 10% by weight (S,S), with defined dosing ranges and permissive route-of-administration embodiments, including inhalation (approx. 1–100 µg/day, with dependent ranges to 6–25 µg/day and 12–25 µg/day), oral (approx. 0.1–1 mg/day), and a fumarate dehydrate salt embodiment.

Claim 1: Core infringement hook

Claim 1 is the independent claim and defines four essential claim elements:

Disease: COPD treatment in a human.
Active ingredient: (R,R)-formoterol or pharmaceutically acceptable salt.
Enantiomeric composition: ≥90% (R,R) and <10% (S,S) by weight.
Therapeutic administration: administering a therapeutically effective amount.

Practical scope implications

The patent is not limited to a single formulation excipient. The claims are method-based and allow salt forms.
The enantiomeric purity threshold is the most objective, product-level boundary. Enantiomeric composition is a direct measurement parameter that can be attacked via analytical results tied to commercial manufacturing specifications and actual lots.
COPD is the disease constraint. Using the same enantiomerically enriched (R,R)-formoterol for a different therapeutic indication may avoid claim coverage unless other patents cover that indication.

Claims 2–4: Route and salt

Claim 2 expands to multiple routes: subcutaneous injection, intravenous infusion, inhalation, transdermal delivery, or oral.

This is broad on administration route, so competitors cannot avoid infringement simply by shifting delivery modality, unless their route falls outside the listed routes and no other dependent claim covers it.

Claim 3 allows administration with a pharmaceutically acceptable carrier, preserving formulation flexibility.

Claim 4 specifies that the salt may be fumarate dehydrate.

Practical scope implications

A product using (R,R)-formoterol fumarate dehydrate is structurally more likely to land inside the narrower salt-dependent claims (claims 4, 13).
If the commercial salt form differs, claims 4/13 may be avoided, but claims 1/10 still pose risk if the product remains (R,R) ≥90% / (S,S) <10% and is used for COPD.

Claims 5–8: Inhalation dose windows

Claim 5: inhalation, ~1–100 µg/day, single or divided. Claim 6: ~6–25 µg/day. Claim 7: ~12–25 µg/day. Claim 8: dosing is in two to four divided doses (dependent on claim 7’s range).

Practical scope implications

These dependent claims create narrower numeric fences. If a competitor’s marketed inhaled dose is outside 12–25 µg/day (and not within 6–25 µg/day or 1–100 µg/day depending on claim dependency), the narrower claims may be avoided, but claim 1 still exists as long as the administered amount is “therapeutically effective” for COPD using the specified enantiomeric purity.
The dependent dose claims can matter for litigation leverage because they are easier to compare against label dosing.

Claims 9–10: Oral dose windows and adverse-effect positioning

Claim 9: oral, ~0.1–1 mg/day.

Claim 10 modifies claim 1 by adding a functional limitation:

The amount is sufficient to treat COPD but insufficient to cause adverse effects associated with racemic formoterol.

Practical scope implications

This “insufficient to cause adverse effects” language is a pharmacologic/clinical performance limitation. In litigation, it often becomes an evidence question (comparative safety profile, dose-response, and what “adverse effects associated with racemic formoterol” means for the product’s class).
Even if enantiomer purity and COPD indication align, claim 10 introduces a second axis beyond composition: the dose is framed by safety outcomes relative to racemate. If a competitor’s dose is consistent with avoiding those racemate-associated events, claim 10 may be harder to assert than claim 1, but claim 1 remains an independent basis.

Claims 11–18: Mirroring expansion of claim 10

Claims 11–18 replicate the route, carrier, salt, inhalation and oral dosage architecture of claims 2–9, but tied to the additional claim 10 “adverse effects associated with racemic formoterol” limitation.

Which enantiomer purity thresholds drive the infringement risk for (R,R)-formoterol COPD products?

Short answer: The patent draws a compositional line at ≥90% (R,R) and <10% (S,S). Any commercial product whose drug substance spec (and actual lot analysis) falls outside that boundary can be positioned to avoid the key claim element.

How to map the purity requirement to real manufacturing specs

For business and litigation purposes, the key is whether the competitor can demonstrate that:

Total (S,S) impurity/contents is ≥10% by weight in the relevant marketed drug substance, or
the product is not “(R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol” as claimed.

This is typically assessed by stereospecific HPLC/GC with validated methods, and by how the company defines “(R,R)-formoterol content” in COAs.

What if a product is “substantially enriched” but not measured exactly?

Under these claims, “at least 90% by weight” and “less than 10% by weight” are explicit. If a competitor’s specifications use broader descriptors, litigation exposure increases because claim construction may hinge on what constitutes “contains” as used in the claim, potentially capturing products that are manufactured to meet FDA/ICH specs that are still within the claimed band.

What patents protect COPD treatment with (R,R)-formoterol in the US beyond 6,866,839?

Short answer: Based solely on the provided claim text, the landscape elements most likely include:

Other patents covering enantiomerically pure formoterol (drug substance and/or manufacturing),
formoterol salt and polymorph/crystal forms (including fumarate hydrate/dehydrate),
formulation patents for inhalation (device/formulation combinations) and oral dosage forms,
method-of-use patents for COPD dosing regimens,
and possible regulatory exclusivity strategy built on the same active (including NDA/ANDA linkage).

No additional patent numbers, assignees, or cited prior art are included in the prompt, so an enumerated US patent-by-patent landscape cannot be produced without external data.

When does US Patent 6,866,839 expire and how does exclusivity interact with generic entry?

Short answer: Expiration and exclusivity timing cannot be computed from claim text alone. A patent term is driven by the filing date, priority, continuations, and whether any patent term adjustment applies; none of those facts are present here.

What generic entry risks exist for COPD (R,R)-formoterol products under this patent?

Short answer: The main generic risk is the generic’s ability to manufacture and market a product that:

Contains (R,R)-formoterol at ≥90% with <10% (S,S),
Is indicated for COPD treatment,
Is prescribed within the label range that may map to the claims (inhalation µg/day or oral mg/day), and
If asserting claim 10/11/14/15/16/17/18 equivalents, also aligns with dosing that avoids “racemic-associated adverse effects.”

Risk scenario A: Enantiomerically enriched (R,R)-formoterol sold for COPD

If a generic is approved with a COPD label and uses an enriched (R,R) product within the purity band, claim 1 risk is direct.

Risk scenario B: Different salt or different route

Changing from inhalation to transdermal or oral does not necessarily remove risk because claim 2 includes multiple routes and claim 1 is route-free.
Changing to a non-fumarate salt may reduce exposure to the salt-dependent claims (4, 13), but not claim 1/10.

Risk scenario C: Dose outside narrower dependent ranges

A generic might try to position dosing outside 6–25 µg/day or 12–25 µg/day for inhalation, or outside 0.1–1 mg/day orally.
Claim 1 still covers “therapeutically effective amount” unless dosing is argued to fall outside “therapeutically effective” as a claim element, which is harder to defend clinically if the product is still indicated.

How strong are the patent claims for enforcement: composition, indication, and dosage boundaries

Short answer: The claims have a strong objective anchor on enantiomeric composition and a clean disease constraint (COPD). Enforcement strength is highest when the accused product’s drug substance is within ≥90% (R,R) / <10% (S,S) and is marketed for COPD.

Strength drivers

Objective numeric purity thresholds (clear analytical measurements).
Explicit disease limitation (COPD).
Route and salt embodiments broaden coverage.

Potential weakness / litigation pressure points

Claim 10 functional safety limitation (“insufficient to cause adverse effects associated with racemic formoterol”) can become a fact-intensive comparative question.

What formulations are protected by US 6,866,839?

Short answer: The claims do not require a specific excipient/formulation platform; they cover methods using the active defined by enantiomeric purity, as administered alone or with a pharmaceutically acceptable carrier, and optionally as a fumarate dehydrate salt. Therefore, the protected subject matter is primarily drug substance and method-of-use, not device-specific inhalation architectures.

What patent estate considerations matter for licensing or product positioning?

Short answer: The licensing value of this patent centers on:

whether a licensing party can sell an (R,R)-formoterol COPD product with enantiomeric purity in the claimed band, and
whether the dosing strategy maps to the dependent ranges and to “racemate adverse effects” framing.

Actionable negotiation signals

If the commercial process yields (S,S) content near or above 10% by weight, the license leverage shifts toward composition-escape arguments.
If the commercial salt is fumarate dehydrate and the label maps to the inhalation µg/day or oral mg/day ranges, licensing leverage increases.

Key Takeaways

US Patent 6,866,839 is a method-of-treatment patent for COPD using (R,R)-formoterol with ≥90% (R,R) and <10% (S,S).
Enantiomeric purity is the primary objective boundary; it is designed to differentiate from racemic formoterol.
Dependent claims add route flexibility (including inhalation and oral), salt embodiment (fumarate dehydrate), and specific dose windows (inhalation 1–100 µg/day, narrower 6–25 µg/day and 12–25 µg/day; oral 0.1–1 mg/day).
Claim 10 introduces a functional limitation: dosing sufficient for COPD treatment but insufficient to cause racemic-associated adverse effects, which raises a comparative safety evidence dimension.

FAQs

1) Does US 6,866,839 cover inhaled and oral (R,R)-formoterol for COPD?
Yes. Independent claim scope is route-permissive (claim 2/11), and dependent claims define inhalation and oral dosage windows.

2) If a product uses a non-fumarate salt of (R,R)-formoterol, can it avoid the patent?
It may avoid the salt-dependent narrower claims (claims 4/13) but not claim 1/10 if the product meets the enantiomeric purity thresholds and COPD treatment use.

3) What is the single most important chemical parameter in the claims?
The enantiomeric composition: at least 90% by weight (R,R) and less than 10% by weight (S,S).

4) How do dosing choices affect risk under claim 1 versus claims 5–9?
Claim 1 covers “therapeutically effective amount” broadly, while claims 5–9 narrow risk through specific inhalation and oral dose ranges.

5) Is claim 10 easier or harder to enforce than claim 1?
Claim 10 is harder to assert cleanly because it adds a functional safety limitation tied to adverse effects “associated with racemic formoterol,” requiring comparative evidence.

References (APA)

Provided claim text for US Patent 6,866,839 (user-supplied).

Title:	Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Abstract:	A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
Inventor(s):	Gunnar Aberg, John Morley
Assignee:	Sumitomo Pharma America Inc
Application Number:	US10/457,123
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;
Patent landscape, scope, and claims:	United States Patent 6,866,839 (R,R)-Formoterol for COPD: Claim Scope, Patent Landscape, and Expiration/Challenge Pathways Executive summary: US Patent 6,866,839 claims methods for treating chronic obstructive pulmonary disease (COPD) using enantiomerically enriched (R,R)-formoterol with ≥90% (R,R) and <10% (S,S), including dosage ranges and routes (notably inhalation and oral) and a specific salt embodiment (the fumarate dehydrate salt). The practical scope is concentrated on (i) enantiomer purity, (ii) COPD treatment, (iii) selected dosing windows designed to avoid racemic-associated adverse effects, and (iv) specific administration modalities. The competitive freedom-to-operate typically hinges on whether a competitor’s product uses an (R,R)-formoterol drug substance and whether its regulatory-grade enantiomeric purity falls within or outside the claimed purity band, plus whether dosage and “insufficient to cause racemic adverse effects” are structurally satisfied. What is the scope of US Patent 6,866,839 and what do its claims cover? Short answer: The patent covers method-of-treatment claims for COPD using (R,R)-formoterol that is enriched to at least 90% by weight (R,R) and contains less than 10% by weight (S,S), with defined dosing ranges and permissive route-of-administration embodiments, including inhalation (approx. 1–100 µg/day, with dependent ranges to 6–25 µg/day and 12–25 µg/day), oral (approx. 0.1–1 mg/day), and a fumarate dehydrate salt embodiment. Claim 1: Core infringement hook Claim 1 is the independent claim and defines four essential claim elements: Disease: COPD treatment in a human. Active ingredient: (R,R)-formoterol or pharmaceutically acceptable salt. Enantiomeric composition: ≥90% (R,R) and <10% (S,S) by weight. Therapeutic administration: administering a therapeutically effective amount. Practical scope implications The patent is not limited to a single formulation excipient. The claims are method-based and allow salt forms. The enantiomeric purity threshold is the most objective, product-level boundary. Enantiomeric composition is a direct measurement parameter that can be attacked via analytical results tied to commercial manufacturing specifications and actual lots. COPD is the disease constraint. Using the same enantiomerically enriched (R,R)-formoterol for a different therapeutic indication may avoid claim coverage unless other patents cover that indication. Claims 2–4: Route and salt Claim 2 expands to multiple routes: subcutaneous injection, intravenous infusion, inhalation, transdermal delivery, or oral. This is broad on administration route, so competitors cannot avoid infringement simply by shifting delivery modality, unless their route falls outside the listed routes and no other dependent claim covers it. Claim 3 allows administration with a pharmaceutically acceptable carrier, preserving formulation flexibility. Claim 4 specifies that the salt may be fumarate dehydrate. Practical scope implications A product using (R,R)-formoterol fumarate dehydrate is structurally more likely to land inside the narrower salt-dependent claims (claims 4, 13). If the commercial salt form differs, claims 4/13 may be avoided, but claims 1/10 still pose risk if the product remains (R,R) ≥90% / (S,S) <10% and is used for COPD. Claims 5–8: Inhalation dose windows Claim 5: inhalation, ~1–100 µg/day, single or divided. Claim 6: ~6–25 µg/day. Claim 7: ~12–25 µg/day. Claim 8: dosing is in two to four divided doses (dependent on claim 7’s range). Practical scope implications These dependent claims create narrower numeric fences. If a competitor’s marketed inhaled dose is outside 12–25 µg/day (and not within 6–25 µg/day or 1–100 µg/day depending on claim dependency), the narrower claims may be avoided, but claim 1 still exists as long as the administered amount is “therapeutically effective” for COPD using the specified enantiomeric purity. The dependent dose claims can matter for litigation leverage because they are easier to compare against label dosing. Claims 9–10: Oral dose windows and adverse-effect positioning Claim 9: oral, ~0.1–1 mg/day. Claim 10 modifies claim 1 by adding a functional limitation: The amount is sufficient to treat COPD but insufficient to cause adverse effects associated with racemic formoterol. Practical scope implications This “insufficient to cause adverse effects” language is a pharmacologic/clinical performance limitation. In litigation, it often becomes an evidence question (comparative safety profile, dose-response, and what “adverse effects associated with racemic formoterol” means for the product’s class). Even if enantiomer purity and COPD indication align, claim 10 introduces a second axis beyond composition: the dose is framed by safety outcomes relative to racemate. If a competitor’s dose is consistent with avoiding those racemate-associated events, claim 10 may be harder to assert than claim 1, but claim 1 remains an independent basis. Claims 11–18: Mirroring expansion of claim 10 Claims 11–18 replicate the route, carrier, salt, inhalation and oral dosage architecture of claims 2–9, but tied to the additional claim 10 “adverse effects associated with racemic formoterol” limitation. Which enantiomer purity thresholds drive the infringement risk for (R,R)-formoterol COPD products? Short answer: The patent draws a compositional line at ≥90% (R,R) and <10% (S,S). Any commercial product whose drug substance spec (and actual lot analysis) falls outside that boundary can be positioned to avoid the key claim element. How to map the purity requirement to real manufacturing specs For business and litigation purposes, the key is whether the competitor can demonstrate that: Total (S,S) impurity/contents is ≥10% by weight in the relevant marketed drug substance, or the product is not “(R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol” as claimed. This is typically assessed by stereospecific HPLC/GC with validated methods, and by how the company defines “(R,R)-formoterol content” in COAs. What if a product is “substantially enriched” but not measured exactly? Under these claims, “at least 90% by weight” and “less than 10% by weight” are explicit. If a competitor’s specifications use broader descriptors, litigation exposure increases because claim construction may hinge on what constitutes “contains” as used in the claim, potentially capturing products that are manufactured to meet FDA/ICH specs that are still within the claimed band. What patents protect COPD treatment with (R,R)-formoterol in the US beyond 6,866,839? Short answer: Based solely on the provided claim text, the landscape elements most likely include: Other patents covering enantiomerically pure formoterol (drug substance and/or manufacturing), formoterol salt and polymorph/crystal forms (including fumarate hydrate/dehydrate), formulation patents for inhalation (device/formulation combinations) and oral dosage forms, method-of-use patents for COPD dosing regimens, and possible regulatory exclusivity strategy built on the same active (including NDA/ANDA linkage). No additional patent numbers, assignees, or cited prior art are included in the prompt, so an enumerated US patent-by-patent landscape cannot be produced without external data. When does US Patent 6,866,839 expire and how does exclusivity interact with generic entry? Short answer: Expiration and exclusivity timing cannot be computed from claim text alone. A patent term is driven by the filing date, priority, continuations, and whether any patent term adjustment applies; none of those facts are present here. What generic entry risks exist for COPD (R,R)-formoterol products under this patent? Short answer: The main generic risk is the generic’s ability to manufacture and market a product that: Contains (R,R)-formoterol at ≥90% with <10% (S,S), Is indicated for COPD treatment, Is prescribed within the label range that may map to the claims (inhalation µg/day or oral mg/day), and If asserting claim 10/11/14/15/16/17/18 equivalents, also aligns with dosing that avoids “racemic-associated adverse effects.” Risk scenario A: Enantiomerically enriched (R,R)-formoterol sold for COPD If a generic is approved with a COPD label and uses an enriched (R,R) product within the purity band, claim 1 risk is direct. Risk scenario B: Different salt or different route Changing from inhalation to transdermal or oral does not necessarily remove risk because claim 2 includes multiple routes and claim 1 is route-free. Changing to a non-fumarate salt may reduce exposure to the salt-dependent claims (4, 13), but not claim 1/10. Risk scenario C: Dose outside narrower dependent ranges A generic might try to position dosing outside 6–25 µg/day or 12–25 µg/day for inhalation, or outside 0.1–1 mg/day orally. Claim 1 still covers “therapeutically effective amount” unless dosing is argued to fall outside “therapeutically effective” as a claim element, which is harder to defend clinically if the product is still indicated. How strong are the patent claims for enforcement: composition, indication, and dosage boundaries Short answer: The claims have a strong objective anchor on enantiomeric composition and a clean disease constraint (COPD). Enforcement strength is highest when the accused product’s drug substance is within ≥90% (R,R) / <10% (S,S) and is marketed for COPD. Strength drivers Objective numeric purity thresholds (clear analytical measurements). Explicit disease limitation (COPD). Route and salt embodiments broaden coverage. Potential weakness / litigation pressure points Claim 10 functional safety limitation (“insufficient to cause adverse effects associated with racemic formoterol”) can become a fact-intensive comparative question. What formulations are protected by US 6,866,839? Short answer: The claims do not require a specific excipient/formulation platform; they cover methods using the active defined by enantiomeric purity, as administered alone or with a pharmaceutically acceptable carrier, and optionally as a fumarate dehydrate salt. Therefore, the protected subject matter is primarily drug substance and method-of-use, not device-specific inhalation architectures. What patent estate considerations matter for licensing or product positioning? Short answer: The licensing value of this patent centers on: whether a licensing party can sell an (R,R)-formoterol COPD product with enantiomeric purity in the claimed band, and whether the dosing strategy maps to the dependent ranges and to “racemate adverse effects” framing. Actionable negotiation signals If the commercial process yields (S,S) content near or above 10% by weight, the license leverage shifts toward composition-escape arguments. If the commercial salt is fumarate dehydrate and the label maps to the inhalation µg/day or oral mg/day ranges, licensing leverage increases. Key Takeaways US Patent 6,866,839 is a method-of-treatment patent for COPD using (R,R)-formoterol with ≥90% (R,R) and <10% (S,S). Enantiomeric purity is the primary objective boundary; it is designed to differentiate from racemic formoterol. Dependent claims add route flexibility (including inhalation and oral), salt embodiment (fumarate dehydrate), and specific dose windows (inhalation 1–100 µg/day, narrower 6–25 µg/day and 12–25 µg/day; oral 0.1–1 mg/day). Claim 10 introduces a functional limitation: dosing sufficient for COPD treatment but insufficient to cause racemic-associated adverse effects, which raises a comparative safety evidence dimension. FAQs 1) Does US 6,866,839 cover inhaled and oral (R,R)-formoterol for COPD? Yes. Independent claim scope is route-permissive (claim 2/11), and dependent claims define inhalation and oral dosage windows. 2) If a product uses a non-fumarate salt of (R,R)-formoterol, can it avoid the patent? It may avoid the salt-dependent narrower claims (claims 4/13) but not claim 1/10 if the product meets the enantiomeric purity thresholds and COPD treatment use. 3) What is the single most important chemical parameter in the claims? The enantiomeric composition: at least 90% by weight (R,R) and less than 10% by weight (S,S). 4) How do dosing choices affect risk under claim 1 versus claims 5–9? Claim 1 covers “therapeutically effective amount” broadly, while claims 5–9 narrow risk through specific inhalation and oral dose ranges. 5) Is claim 10 easier or harder to enforce than claim 1? Claim 10 is harder to assert cleanly because it adds a functional safety limitation tied to adverse effects “associated with racemic formoterol,” requiring comparative evidence. References (APA) Provided claim text for US Patent 6,866,839 (user-supplied). More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9107196	Apr 05, 1991

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Belgium	1005778	⤷ Start Trial
Canada	2065051	⤷ Start Trial
Switzerland	685672	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,866,839

Summary for Patent: 6,866,839

What is the scope of US Patent 6,866,839 and what do its claims cover?

Claim 1: Core infringement hook

Claims 2–4: Route and salt

Claims 5–8: Inhalation dose windows

Claims 9–10: Oral dose windows and adverse-effect positioning

Claims 11–18: Mirroring expansion of claim 10

Which enantiomer purity thresholds drive the infringement risk for (R,R)-formoterol COPD products?

How to map the purity requirement to real manufacturing specs

What if a product is “substantially enriched” but not measured exactly?

What patents protect COPD treatment with (R,R)-formoterol in the US beyond 6,866,839?

When does US Patent 6,866,839 expire and how does exclusivity interact with generic entry?

What generic entry risks exist for COPD (R,R)-formoterol products under this patent?

Risk scenario A: Enantiomerically enriched (R,R)-formoterol sold for COPD

Risk scenario B: Different salt or different route

Risk scenario C: Dose outside narrower dependent ranges

How strong are the patent claims for enforcement: composition, indication, and dosage boundaries

Strength drivers

Potential weakness / litigation pressure points

What formulations are protected by US 6,866,839?

What patent estate considerations matter for licensing or product positioning?

Key Takeaways

FAQs

References (APA)

Drugs Protected by US Patent 6,866,839

Foreign Priority and PCT Information for Patent: 6,866,839

International Family Members for US Patent 6,866,839

Make Better Decisions: Try a trial or see plans & pricing